Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOVANTRONE vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Treatment of acute nonlymphocytic leukemia (ANLL) in adults (in combination with other agents),Treatment of advanced hormone-refractory prostate cancer (in combination with corticosteroids),Treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (to reduce neurologic disability and frequency of clinical relapses)
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Mitoxantrone is extensively metabolized in the liver via oxidation and conjugation, primarily by cytochrome P450 enzymes, forming inactive metabolites. Elimination is mainly via the hepatobiliary system with fecal excretion; small amounts are excreted renally.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
~78% bound to plasma proteins (primarily albumin).
Approximately 20–30% bound to plasma proteins.
Mean Vd: 8-22 L/kg (range 6-44 L/kg). Large Vd indicates extensive tissue distribution and binding to intracellular components.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Intravenous: 100% (only route of administration). Oral bioavailability is <5% and not clinically relevant; no other routes used.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment required for GFR >50 m L/min. For GFR 10-50 m L/min: administer 75% of normal dose. For GFR <10 m L/min: administer 50% of normal dose.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25%. Child-Pugh Class C: reduce dose by 50%.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established; not recommended for pediatric use.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
Monitor cardiac function closely due to increased risk of cardiotoxicity. Higher risk of myelosuppression; consider lower initial doses based on renal function (see renal adjustment).
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
1. Mitoxantrone should be administered under the supervision of a physician experienced in the use of cancer chemotherapy agents. 2. Cardiac toxicity, including congestive heart failure, can occur and may be cumulative; risk increases with prior anthracycline use, mediastinal radiotherapy, pre-existing cardiac disease, or concomitant cardiotoxic drugs. 3. Secondary acute myeloid leukemia (AML) has been reported in patients treated with mitoxantrone-containing regimens. 4. Severe myelosuppression will occur.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Cardiotoxicity: Monitor left ventricular ejection fraction (LVEF) before and during therapy; cumulative dose limit of 140 mg/m² in multiple sclerosis patients.,Myelosuppression: Severe neutropenia, thrombocytopenia, and anemia; monitor complete blood counts regularly.,Secondary malignancies: Increased risk of AML and myelodysplastic syndrome.,Hepatic impairment: Dose reduction may be necessary; monitor liver function.,Renal impairment: Use with caution; adjust dose if severe.,Immunosuppression: Increased risk of infections; avoid live vaccines.,Pregnancy: Can cause fetal harm; advise effective contraception.,Extravasation: Can cause tissue necrosis; administer via IV with care.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to mitoxantrone or any component of the formulation,Significant pre-existing bone marrow suppression (e.g., baseline neutrophil count <1500/mm³, platelet count <50,000/mm³),Patients with clinically significant cardiac disease (e.g., myocardial infarction within 6 months, unstable angina, severe heart failure)
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice as it may theoretically interfere with metabolism, though not clinically significant.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major congenital malformations. Second and third trimester exposure may cause fetal growth restriction, myelosuppression, and cardiac toxicity. Use during pregnancy is contraindicated unless the potential benefit outweighs the risk.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
Mitoxantrone is excreted into human breast milk; the milk-to-plasma ratio is not well characterized. Due to the potential for serious adverse reactions in nursing infants, including immunosuppression and cardiotoxicity, breastfeeding is contraindicated during therapy and for at least 1 month after the last dose.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No specific dose adjustments are established for pregnancy. However, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Dose adjustment based on body surface area and close monitoring for toxicity are recommended. Use lowest effective dose and consider alternative therapies if possible.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Mitoxantrone is a topoisomerase II inhibitor and anthracenedione; cumulative lifetime dose should not exceed 140 mg/m² due to dose-dependent cardiotoxicity. Pre-treatment LVEF must be assessed and monitored regularly. Administration requires cardiac monitoring during infusion due to risk of arrhythmias.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Report any shortness of breath, cough, or swelling of ankles/feet immediately as these may indicate heart problems.,Urine may turn blue-green for 24-48 hours after infusion; this is harmless.,Avoid live vaccines during treatment and for 6 months after.,Use effective contraception during and for at least 4 months after therapy due to risk of fetal harm.,Notify your doctor if you experience easy bruising, bleeding, fever, or signs of infection.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NOVANTRONE vs CLADRIBINE, answered by our medical review team.
NOVANTRONE is a Antineoplastic Agent that works by Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOVANTRONE and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOVANTRONE is: 12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOVANTRONE and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOVANTRONE is classified as Category C. Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major conge. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.